Our team
Seung-Hoon Lee, MD, PhD, FAHA
CEO
Dr. Seung-Hoon Lee leads the world’s first CDMO dedicated solely to nanomedicine. With a distinguished background in clinical medicine, translational research, and pharmaceutical development, he brings a deep understanding of the challenges in advancing nanoparticle-based therapeutics. He leads the company in delivering integrated, GMP-compliant solutions that help partners advance and scale nanoparticle-based therapeutics.
Bong Geun Cha, PhD
CTO
Dr. Bong Geun Cha, CTO and Director of the Corporate Research Institute at OmniParticles, is an expert in chemical engineering with a focus on nanomedicine. He holds a Ph.D. in Chemical Engineering from Sungkyunkwan University and has conducted research at Harvard University. At OmniParticles, he leads innovation and R&D, driving advancements in nanoparticle-based drug development and manufacturing.
Moon-Sun Choi, MPH
CMO
Moon-Sun Choi is a regulatory affairs specialist with over 18 years of experience. She has led regulatory strategies and clinical programs across multiple therapeutic areas at Celltrion, ensuring compliance with global health authorities. With extensive experience overseeing CROs, managing regulatory submissions, and navigating inspections, she provides expert regulatory support to streamline drug development and approval processes.
Yong-Sun Park, MS
Team Leader at R&D
Yong-Sun Park, M.S. in Chemical and Biological Engineering, has 15+ years of expertise in nanomaterial synthesis and applications. He co-founded and led R&D at a biotech startup on nanoparticle drug delivery for refractory cancers, driving material development, preclinical studies, and regulatory strategy. At CENYX, he advances drug discovery and pipeline growth through nanomaterial design, CMC development, and cross-functional R&D.
Tae Eun Kim, MS
Team Leader at R&D
Tae Eun Kim specializes in nanoparticle-based drug development, process optimization, and pilot-scale manufacturing. With expertise in nanoparticle synthesis, molecular diagnostics, and therapeutic formulation, he plays a key role in advancing nanomedicine innovations.
Byoung Soo Kim, PhD
Sr. Researcher at Preclinical R&D
Byoungsoo Kim contributes deep scientific expertise to preclinical programs with a PhD in Biological Sciences from KAIST and a research focus in neuroscience. His experience in experimental design, data interpretation, and academic research supports the development of innovative nanomedicine platforms.
GunJu Sun, PhD
GMP & CMC Specialist
Gunju Sun specializes in nanomaterial synthesis, process optimization, and quality control in pharmaceutical manufacturing. With expertise in CMC, he ensures compliance with GMP standards and enhances the efficiency of nanoparticle-based drug production. His background in materials science and engineering supports the development of high-quality nanomedicines.
Yong-Sung Jeon
GMP Specialist
Yong-Sung Jun brings nearly 8 years of experience in animal nutrition and manufacturing operations. He supports GMP compliance through SOP development, equipment qualification, and cleanroom operations
Jaewon Lee
CMC Specialist
Jaewon Lee supports CMC development with expertise in pharmaceutical sciences and biochemistry. With experience in anticancer drug research and analytical method development, he ensures the stability and quality of drug substances while supporting cGMP compliance and regulatory documentation.
Hangyeom Cho, PharmD.
Quality Assurance Manager
Hangyeom Cho is a highly experienced quality and regulatory expert with over 15 years of experience across drugs, medical devices, and cosmetics. She has led QA and RA departments, managed GMP and GSP compliance, and served as a Qualified Person for drug import. With hands-on experience handling audits from MFDS and PMDA, she brings robust regulatory insight and quality system leadership to ensure product integrity and global compliance.
Jin Young Chung, PharmD.
Sr. BD Manager
Jinyoung Chung, a licensed pharmacist, brings experience in clinical operations and strategic partnerships. Before joining OmniParticles, he led BD activities in licensing and technology transfer at Handok Inc. and managed quality systems for clinical trial materials at Marken Korea. At OmniParticles, he drives global business development, forging partnerships and supporting clients in advancing nanomedicine programs.
Jong Seo Kim
BD Specialist
Jong Seo Kim supports business development at Omniparticles through market research, global communication, and partnership outreach. With a degree in life sciences and biotechnology from Yonsei University and fluency in multiple languages, he helps bridge scientific innovation with business opportunities in the nanomedicine field.